Multidrug- and extensively drug-resistant tuberculosis: An emerging threat

European Respiratory Review

Volumn 18, Issue 114, 2009, Pages 195-197

  Berry, M ^a,b   Kon, O M ^a,c  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b National Institute for Medical Research

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; GAMMA INTERFERON; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PLACEBO; RIFAMPICIN; STREPTOMYCIN; VITAMIN D;

ANEMIA; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG WITHDRAWAL; EASTERN EUROPE; EDITORIAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; POLYNEUROPATHY; POPULATION; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 73449123415     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00005209     Document Type: Editorial

References (27)

1. Koch R. Die Aetiologie der Tuberculose [The Aetiology of Tuberculosis]. Berlin, Berliner Klinische Wochenschrift, 1882.
2. World Health Organization. WHO Factsheet Number 310: The 10 Leading Causes of Death by Broad Income Group (2004). Geneva, World Health Organization, 2008.
3. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report 2008. Geneva, World Health Organization, 2008.
4. Sasse J, Teichmann D. Disseminated multiorgan MDR-TB resistant to virtually all first-line drugs. Eur Respir Rev 2009; 18: 291-294.
5. Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373: 1861-1873.
6. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33: 1085-1094.
7. Centers for Disease Control and Prevention. Notice to readers: revised definition of extensively drug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep 2006; 55: 1176.
8. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
9. Shah NS, Wright A, Bai GH, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387.
10. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
11. Migliori GB, Besozzi G, Girardi E, et al. Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623-626.
12. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28: 980-985.
13. Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
14. Chan ED, Strand MJ, Iseman MD. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB. Clin Infect Dis 2009; 48: e50-e52.
15. Migliori GB, Lange C, Girardi E, et al. Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008; 31: 904-905.
16. Keshavjee S, Gelmanova IY, Farmer PE, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet 2008; 372: 1403-1409.
17. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
18. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
19. Bwanga F, Hoffner S, Haile M, et al. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis 2009; 9: 67.
20. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005; 25: 564-569.
21. Taegtmeyer M, Beeching NJ, Scott J, et al. The clinical impact of nucleic acid amplification tests on the diagnosis and management of tuberculosis in a British hospital. Thorax 2008; 63: 317-321.
22. Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
23. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
24. Martineau AR, Honecker FU, Wilkinson RJ, et al. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol 2007; 103: 793-798.
25. Reljic R. IFN-γ therapy of tuberculosis and related infections. J Interferon Cytokine Res 2007; 27: 353-364.
26. Rook GA, Lowrie DB, Hernandez-Pando R. Immunotherapeutics for tuberculosis in experimental animals: is there a common pathway activated by effective protocols? J Infect Dis 2007; 196: 191-198.
27. Kim HJ, Kang CH, Kim YT, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis. Eur Respir J 2006; 28: 576-580.